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A Novel Test for Recessive Contributions
to Complex Diseases Implicates Bardet-Biedl Syndrome
Gene BBS10 in Idiopathic Type 2 Diabetes and Obesity
Elaine T. Lim,1,2,3,4,18,* Yangfan P. Liu,5,18 Yingleong Chan,3,4,6,18 Tuomi Tiinamaija,7,8,9
AnnMari Ka¨ra¨ja¨ma¨ki,10,11 Erik Madsen,5 Go-T2D Consortium, David M. Altshuler,3,4,12
Soumya Raychaudhuri,4,13,14 Leif Groop,15,16 Jason Flannick,4,12 Joel N. Hirschhorn,3,4,6,18
Nicholas Katsanis,5,18 and Mark J. Daly4,17,18,*
Rare-variant association studies in common, complex diseases are customarily conducted under an additive risk model in both single-
variant and burden testing. Here, we describe a method to improve detection of rare recessive variants in complex diseases termed RAFT
(recessive-allele-frequency-based test).We found that RAFToutperforms existing approaches when the variant influences disease risk in a
recessive manner on simulated data. We then applied our method to 1,791 Finnish individuals with type 2 diabetes (T2D) and 2,657
matched control subjects. In BBS10, we discovered a rare variant (c.1189A>G [p.Ile397Val]; rs202042386) that confers risk of T2D in
a recessive state (p¼ 1.383 106) and would be missed by conventional methods. Testing of this variant in an established in vivo zebra-
fishmodel confirmed the variant to be pathogenic. Taken together, these data suggest that RAFTcan effectively reveal rare recessive con-
tributions to complex diseases overlooked by conventional association tests.Introduction
Genome-wide association studies (GWASs) have identified
numerous additive genomic variants associated with com-
plex disorders,1 which appear to impact liability to disease
(or affect a normally distributed trait) linearly with an
effect size of a when heterozygous and 2a when homozy-
gous. Most of these variants are common (R5% frequency)
and have only small effect sizes (odds ratio [OR] < 1.2) on
complex disease classifications. However, such variants do
not explain the full heritability of disease. As rare variants
have been comparatively less well studied, attention has
shifted to exome- or genome-sequence-based approaches
to identifying additional risk factors. Another less-well-
explored hypothesis is that there might be variants that in-
fluence disease susceptibility in a nonadditive fashion, for
instance, if the variants influence disease risk recessively,
that is, only when the minor allele is found in a homozy-
gous state, or in trans with another minor allele to form
compound heterozygotes. However, most widely used tests
for disease association, such as allele-based regression tests
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The Americanadditive model. Such approaches are well powered to
detect common alleles even if they influence disease risk
in a nonadditive fashion. Common variants in genes
such as FUT2 (MIM 182100) and TYRP1 (MIM 115501)
have also been demonstrated to influence complex dis-
eases and traits in a recessive manner;2,3 these loci were
detected by the typical additive approaches because there
are many homozygotes observed for these common vari-
ants and therefore strong signal exists even under the addi-
tive model.4
In contrast, the power of the additive model to detect
recessive alleles diminishes greatly at lower frequencies,
since the numbers of homozygotes observed are far fewer.
Consequently, if there are rare variants that confer signifi-
cant risk of the phenotype in a recessive manner, conven-
tional tests are underpowered to detect such variants
in complex diseases. However, extensive runs of homozy-
gosity have been associated with complex diseases and
traits such as height5 (MIM 606255), schizophrenia6
(MIM 181500), and autism spectrum disorders7,8 (MIM
209850), suggesting that rare recessive variants in these re-
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spectrum disorders, further studies have shown that there
is a strong signal from recessively acting rare variants
involved in the disease etiology.9,10 Moreover, since a
high proportion of rare Mendelian disease alleles confer
risk in a strictly dominant or recessive fashion, testing for
nonadditive effects of rare variants in common, complex
diseases might well yield fruitful associations missed by
conventional association tests.
We describe a statistical methodology (termed RAFT for
recessive allele frequency-based test) designed specifically
for detecting variants with recessive effects on a dichoto-
mous phenotype. We demonstrate that RAFT has consider-
ably more power to detect disease-associated rare variants
than conventional approaches. In applying RAFT to an
exome chip data set comprising 4,448 individuals, 1,791
of whom are case subjects with type 2 diabetes (T2D
[MIM 125853]), we detected a rare variant in Bardet-Biedl
syndrome 10 (BBS10 [MIM 610148]) that confers signifi-
cant risk of T2D in a recessive manner (p ¼ 1.38 3 106).
Functional testing of this allele in vivo confirmed its effect
on protein function, providing further support for the ge-
netic association. Thus, increasing power for specific
modes of inheritance offers the potential to discover novel
associations in common complex diseases (as it clearly has
in rare diseases), particularly for rare recessive variants for
which conventional statistical methods are bereft of
power.Material and Methods
Exome Chip Genotyping and Quality Control
The DNA samples were obtained from the Botnia and Direva
Studies. For genotyping, the samples were sent to the Broad Insti-
tute and prepared for genetic analysis with two quality-control
measures. First, DNA quantity was measured by Picogreen, and
then all samples with sufficient total DNA and minimum concen-
trations for downstream activities were genotyped for a set of 24
SNPs with the Sequenom iPLEX Assay. These 24 validated markers
include 1 gender assay and 23 SNPs located across the autosomes.
The genotypes for these SNPs were used as a quality filter to
advance samples, as well as a technical fingerprint validation
(when applicable) for array genotypes. This study was approved
by the MGH/Broad/HMS institutional review board, and appro-
priate informed consent was obtained from human subjects.
All genotyping was performed at the Broad Institute Genetic
Analysis Platform. DNA samples were placed on 96-well plates
and genotyped with the Illumina HumanExome v.1.1 SNP array.
Genotypes were assigned with GenomeStudio v.2010.3 and the
calling algorithm/genotyping module v.1.8.4 with the custom
cluster file HumanExomev1_1_CEPH_A.egt. Subsequent process-
ing of genotype calling was done by zCall.11 Samples with two
or more discordant fingerprint genotypes and/or call rates below
97% were excluded from data analysis. Individuals with call rates
below 99% were excluded from analysis, as were SNVs with call
rates below 80% or with extreme deviations (p < 1 3 108) from
Hardy-Weinberg equilibrium (HWE). The accuracy of genotypes
for the BBS10 c.1189A>G variant was assessed via visual inspec-
tion of intensity plots (Figure S1, available online).510 The American Journal of Human Genetics 95, 509–520, NovembCase-Control Principal-Component Analysis and
Matching
Principal-component analysis was performed on a set of
linkage-disequilibrium-independent SNPs with PLINK12 and
EIGENSTRAT.13 In addition, to reduce heterogeneity between
the case and control subjects, we performed one-to-one matching
for each case-control pair by using the first ten principal compo-
nents and selecting the closest matched control for each case.
Case-control pairs with a sum of the absolute differences in the
first ten principal components of >0.06 were removed from the
analyses. In addition, cases with excessive relatedness (identity
by descent > 0.2) were removed from the analyses.Data Filtering and Annotation
In addition, all variants with heterozygous counts of%3 (allele fre-
quency of ~0.025%) in case and control subjects were removed to
reduce the number of variants that were miscalled as rare homozy-
gotes instead of heterozygotes. To further reduce genotyping
errors, variants with HWE p values of %1 3 103 in the controls
were removed. The variants were then annotated with the Variant
Effect Predictor.Estimating the Probability of Observing Homozygotes
The key factor in any homozygosity analysis is the probability of
minor allele (a) being homozygous P(aa), which in theory is simply
P(a)2 and is estimated directly from the observed allele counts. Two
scenarios exist when this expectation may not be met and can be
readily accommodated up front in this analysis framework. Sub-
structure or consanguinity in a population can cause global depar-
ture fromHWE, resulting in systematic genome-wide excess homo-
zygosity. In such cases, we can fit a regression to all variants in the
data set to estimate a substructure or homozygosity by descent fac-
tor F by using the standardmodel P(aacorrected)¼ FP(a)þ (1 F)P(a)2
and can then utilize this corrected value as P(aa) below. This might
be important for analysis of populations with high inbreeding.
Additionally, in actual genotyping and sequencing data, we
encounter occasions where local departures from HWE in control
subjects (as well as case subjects) are observed as a result of hemi-
zygous deletions or systematic genotyping errors.While such local
genotyping artifacts can be detected and avoided inmanyways, in
cases where the observed rate of homozygous genotypes in control
subjects exceeds the expected corrected P(aa), we can conserva-
tively set the P(aa) used below to the higher observed rate in
control subjects, thereby insuring that the probability of homozy-
gosity that the test statistic relies on is insulated from both global
and local sources of inflation.RAFT Statistics
Under the alternative hypothesis described below, the maximum-
likelihood estimate of P(aa) is altered slightly (since excess homo-
zygosity in cases is presumed to arise from case ascertainment), but
this difference is generally negligible and not tested as a parameter
in the association test below. Under the alternative hypothesis of
recessive association, the probability of the minor allele being ho-
mozygous in a case P(aa j case, g), given a genotypic relative risk to
homozygotes (g), is
Pðaa j case;gÞ ¼ gPðaaÞ
1 PðaaÞ þ gPðaaÞ:
And the probability of not observing a homozygote for the minor
allele in a case subject iser 6, 2014
Pðaa j case;gÞ ¼ 1 Pðaa j case;gÞ:
The alternative calculation for homozygotes for the minor allele
in control subjects P(aa j control, g) is similar. However, for selected
control subjects, the formulation includes the estimated preva-
lence of the disease (f), which we have fixed as a constant to 1 in
100,000. For convenience, we use the variable x to represent the
prevalence of disease in control individuals where x ¼ f=ð1
PðaaÞ þ gPðaaÞÞ, which is the prevalence under the null. As such,
P(aa j control, g) and Pðaajcontrol;gÞ can be calculated by
Pðaa j control;gÞ ¼ ð1 gxÞPðaaÞ
1 f
and Pðaajcontrol;gÞ ¼ 1 Pðaajcontrol;gÞ.
And the resulting likelihood of the observation of ncaseaa number
of alternate homozygotes in the case subjects, ncaseaa number of
heterozygotes and reference homozygotes in the case subjects,
ncontrolaa number of alternate homozygotes in the control subjects,
ncontrolaa number of heterozygotes and reference homozygotes in
the control subjects, is proportional to
L

ncaseaa ;ncaseaa

 Pðaa j case;gÞncaseaa ½Pðaa j case;gÞncasencaseaa
3Pðaa j control;gÞncontrolaa ½Pðaa j control;gÞncontrolncontrolaa
or
L

ncaseaa ;ncaseaa

 Pðaa j case;gÞncaseaa ½1 Pðaa j case;gÞncasencaseaa
3Pðaa j control;gÞncontrolaa ½1 Pðaa j control;gÞncontrolncontrolaa
where ncase is the total number of case subjects and ncontrol is the
total number of control subjects. We next performed an expecta-
tion maximization (EM) step to maximize the log likelihood ratios
between the alternate model L1 and the null model L0, to obtain
the following RAFT statistic:
RAFT ¼ log10
2
4L1

ncaseaa ;ncaseaa ;ncontrolaa ;ncontrolaa

L0

ncaseaa ;ncaseaa ;ncontrolaa ;ncontrolaa

3
5
orRAFT ¼ log10
"
Pðaa j case;g ¼ gcaseÞncaseaa ½1 Pðaa j case;g ¼ gcaseÞncasencaseaa
Pðaa j case;g ¼ 1Þncaseaa ½1 Pðaa j case;g ¼ 1Þncasencaseaa
3
Pðaa j control;g ¼ gcaseÞncontrolaa ½1 Pðaa j case;g ¼ gcaseÞncontrolncontrolaa
Pðaa j control;g ¼ 1Þncontrolaa ½1 Pðaa j control;g ¼ 1Þncontrolncontrolaa
#where gcase is equivalent to the OR of the alternate homozygotes
for the variant. To calculate a p value, we can estimate the following
to a chi-square distribution with 1 degree of freedom (cdf¼1):2 ln
"
Pðaa j case;g ¼ gcaseÞncaseaa ½1 Pðaa j case;g ¼
Pðaa j case;g ¼ 1Þncaseaa ½1 Pðaa j case;g ¼
3
Pðaa j control;g ¼ gcaseÞncontrolaa
Pðaa j control;g ¼ 1Þncontrolaa ½
The AmericanSimulations UsingWhole-Exome Sequencing Data for
Finns and NFEs
We used two different populations—Finns and non-Finnish Euro-
peans (NFEs)—to simulate a scenario where the samples used in
the association are not homogeneously from a single population
even if case and control subjects are well matched. Using whole-
exome sequencing data available for Finns and NFEs,14 we
randomly sampled genotypes from 2,500 Finns and 2,500 NFEs
and assigned them as case subjects. Similarly, we randomly
sampled genotypes for another 2,500 Finns and 2,500 NFEs and
assigned them as control subjects. For each variant, we calculated
the number of individuals that were heterozygous or homozygous
for the minor allele in both case and control subjects. To test the
RAFT statistic in a simulated data set without population substruc-
ture, we simulated genotypes of 5,000 Finns as case subjects and
5,000 Finns as control subjects. These simulations were repeated
100 times to obtain the 95% confidence interval for the distribu-
tion of p values calculated with the RAFT statistic.
Microinjection and Morphometric Analysis of
Zebrafish Embryos
Translation blocker (TB) morpholinos against zebrafish bbs10were
synthesized by Gene Tools (50-CGTTAAACCTCTTCTGTGAAC
CAGC-30). Human BBS10 mRNA was in vitro transcribed with
mMESSAGE mMACHINE SP6 Kit (Ambion). A volume of 0.5 nl
mixture of 5 ng bbs10 TB and/or 75 pg mRNA was microinjected
into the yolk of embryos at the 1- to 8-cell stage. At the 9- to 10-
somite stage, embryos were analyzed for convergent extension de-
fects according to previously established phenotypic criteria.15–17
Glucose Tolerance Test
At 1 day postfertilization (dpf), zebrafish embryos were dechorio-
nated and transferred into egg water (recipe in Westerfield18)
with 1% D-glucose. At 4 dpf, total RNA was extracted from
zebrafish embryos with Trizol (Invitrogen) and then reverse tran-
scripted into cDNA with SuperScript III (Invitrogen), to provide
template for real-time qPCR. The expression levels of pdk2 and
runx1, as well as gapdh for internal control, were examined withthe following primers: dr-pdk2-qF, 50-CGAATTAGCCAATAAAC
CAACAAA-30; dr-pdk2-qR, 50-CACACTTCACCTGCATTTCCA-30;
dr-runx1-qF, 50-CGTCTTCACAAACCCTCCTCAA-30; dr-runx1-qR,gcaseÞncasencaseaa
1Þncasencaseaa
½1 Pðaa j case;g ¼ gcaseÞncontrolncontrolaa
1 Pðaa j control;g ¼ 1Þncontrolncontrolaa
#
 cdf¼1:
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Figure 1. Scenarios to Illustrate p Values Obtained with Fisher’s
Exact Test on the Homozygous Counts
(A) p values obtained if there are 1, 2, 4, 8, 20, or 40 genes with
complete penetrance that are causal for the disease.
(B) p values with different percentages of variance explained by
the homozygotes (aa) in the cases, assuming complete penetrance.
This is an ideal scenario and the power for detection will be lower
if the variants exhibit incomplete penetrance or if there are fewer
controls available.50-GCTTTACTGCTTCATCCGGCT-30; dr-gapdh-qF, 50-TTGTAAG
CAATGCCTCCTGC-30; dr-gapdh-qR, 50-CTGTGTTGCTGTGATGG
CAT-30.Results
RAFT Statistic
Instead of directly comparing homozygous counts in case
and control subjects, the RAFT statistic evaluates the likeli-
hood of observing the number of homozygotes in the cases
(Ncases) compared to the expected number of homozygotes
given the allele frequency of the variant and normalizes
this by the same statistic for observingNcontrols, the number
of homozygotes in the controls compared to the expected
number of homozygotes. For instance, if there is a variant
(variant A) with 0.5% allele frequency, we would expect to
observe 0.05 homozygotes in 2,000 individuals (0.005 3
0.0053 2,000) for this variant. Similarly, if there is another
variant (variant B) with 5% allele frequency, we would
expect to observe 5 homozygotes in 2,000 individuals
(0.053 0.05 3 2,000). However, if we observed five homo-
zygotes who are case subjects and zero homozygotes who
are control subjects for both variants A and B, the RAFT512 The American Journal of Human Genetics 95, 509–520, Novembstatistic will assign a higher LOD score to variant A than
to variant B because it is more unusual to observe five ho-
mozygotes in the case group for a 0.5% variant than for a
5% variant. The normalization of the log likelihood ratio
with the observation in the control subjects brings in the
case-control comparison and, more importantly, ensures
that the results are adjusted for regions where there is
excessive homozygosity in the control subjects (such as
hemizygous copy-number polymorphic regions, regions
with genotyping errors or arising from unusual substruc-
ture) that might not be truly associated with disease risk.
A conventional test such as Fisher’s exact test will assign
the same probabilities for both variants based on the
observed numbers of homozygotes. However, the RAFTsta-
tistic essentially compares the observed five homozygotes
in the case subjects with the expected number of homo-
zygotes (0.05 for variant A), resulting in increased power.
Greater Power with RAFT for Detecting Rare Variants
under a Recessive Model
To compare RAFT to existing approaches, we performed
simulations to evaluate the power for detecting variants
with allele frequency ranging from 0.1% to 20% that
confer a modest risk (OR ¼ 10) of disease under a recessive
mode of inheritance (Figure 1). We observed that there
might greater than 80% power to detect common recessive
variants (allele frequency > 10%) by using the standard
additive tests (chi-square and transmission disequilibrium
test [TDT]) and that RAFT or a conventional recessive
test (Fisher’s exact test on the homozygous counts [Hom-
FET]) did not confer much advantage over these additive
tests (Figure 2). In contrast, RAFT provides significantly
more power to detect lower-frequency recessive variants
(allele frequency% 5%) than do all the other tests.
Applying RAFT on Previously Reported Recessive
Gene MKKS
We applied the RAFT statistic on a previously published
instance where 2 out of 17 independent families affected
by Bardet-Biedl syndrome (BBS [MIM 209900]) were re-
ported to harbor the same homozygous c.280delT frame-
shift in MKKS19 (MIM 604896). The c.280delT frameshift
was shown to be pathogenic and causal for BBS in these
two families. However, the p value for this observation
calculated by a conventional recessive test such as Hom-
FET is 1.46 3 105, which is shy of the exome-wide signif-
icance threshold of 2.5 3 106 after correcting for 20,000
genes. Instead, by incorporating the allele frequency of
the variant (the c.280delT variant was found to be hetero-
zygous in 1 out of 4,300 individuals of European ancestry
from the NHLBI Exome Variant Server and was found to be
heterozygous in another 2 out of the 17 families affected
by BBS), the p value calculated with RAFT for this observa-
tion is highly significant at 2.263 109. In an exome-wide
screen involving several more families andmanymore var-
iants, it is thus possible that a conventional test might
miss the association between the MKKS c.280delT varianter 6, 2014
Figure 2. Power Calculations for Various Tests in Detecting
Recessive Variants with OR ¼ 10 and Disease Prevalence of 1%
in 5,000 Case Subjects and 5,000 Control Subjects
(A) Power calculations for detecting recessive variants across
different allele frequencies by using two allelic tests (chi-square
and TDT), as well as two recessive tests (Fisher’s exact test on the
homozygotes [Hom-FET] and RAFT).
(B) Graphical representation for the power calculations for chi-
square, TDT, Hom-FET, and RAFT across various allele-frequency
ranges from 0.1% to 20% with the same parameters.
(C) Power calculations for the same scenario but a variant
with 2% allele frequency across various recessive ORs from 1.2
to 2,000.
The Americanand BBS while the RAFT statistic flags this variant as highly
significant.The RAFT Statistic Conforms to the Null Hypothesis
when Tested on a Simulated Finnish Data Set
To evaluate the null behavior of our test statistic, we per-
formed RAFT analysis on simulated data by using allele
frequencies from a whole-exome sequencing data set
composed of 3,000 individuals of Finnish ancestry and
3,000 NFEs14 and consisting of 590,003 coding region var-
iants. For each variant, we randomly simulated 5,000 case
subjects and 5,000 control subjects by using the Finnish
allele frequencies and applied the RAFT analysis. We found
that across all allele frequency bins (common R 5%, low-
frequency 1%–5%, or rare < 1%), we obtained similar
numbers of observed and expected variants in the various
p value bins (Table S1), suggesting that the RAFT statistic
conforms to the null hypothesis when the individuals
are drawn from a homogenous population and there is
no underlying signal of any type.Nonhomogeneous Ancestry CanCause Inflation to the
RAFT Statistic
Given that RAFT is a method designed to test for an excess
of homozygous variants given the allele frequency, arti-
facts in the data that cause deviation from HWE could
inflate the test statistics calculated by RAFT. One such fac-
tor is population stratification. However, similar to existing
genome-wide association studies, this can be detected by
existing methods such as genomic control to identify
whether the case subjects are well-matched to the control
subjects in terms of ancestry. Another more subtle and per-
nicious factor for RAFT is population substructure, where
the case subjects and control subjects may be sampled
equally from a heterogeneous population that consists of
two or more distinct population ancestries. For instance,
if the case subjects and control subjects are derived from
a mixture of Finns and NFEs, this might result in the
Wahlund effect where there is excessive homozygosity
and reduced heterozygosity. Unlike direct case-control
comparisons, where balanced mixtures would not inflate
allele frequency comparisons, such underlying heteroge-
neity can inflate the RAFT statistic.
To evaluate further the effect of population substructure
on RAFT (where the case and control subjects are well
matched for ancestry but contain ethnically different
subpopulations in both case and control subjects), we
randomly generated 5,000 case subjects and 5,000 control
subjects by using equal proportions of Finns and NFEs in
the cases and controls. When we ran the test statistic on
the simulated data, we indeed observed inflation among
the common variants (Table S2). When we performed
additional simulations on just the Finns alone, we did
not observe any significant amount of inflation (Table
S3). Such inflation, if observed, is fully managed by the
inclusion of the F term in the determination of theJournal of Human Genetics 95, 509–520, November 6, 2014 513
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the Material and Methods.
RAFT Discovers a Rare BBS10 Variant Associated
with T2D from T2D Exome Chip Data
We next asked whether we can use RAFT to discover dis-
ease-associated variants by applying existing tests to a set
of exome chip genotyping data for 1,791 T2D case subjects
and 2,657 control subjects of Finnish ancestry matched by
principal-component analysis (Figure S2). A series of qual-
ity control checks were performed to test whether there is
any major population stratification between the case and
control subjects, which will result in global inflation
when running an additive test on the low-frequency and
common variants (R1% allele frequency). However,
Fisher’s exact test on the allele counts (FET) did not show
any evidence for inflation (genomic control l ¼ 1.06,
Figure S3). We note that even though the current sample
size is underpowered to detect the previously published
T2D common variants with genome-wide significance,
the top hit is an intronic variant found in a reported T2D
locus (CDKAL1 [MIM 611259], OR ¼ 1.28, p ¼ 7.75 3
106). Likewise, a conventional recessive test such as
Hom-FET on the common variants detected CDKAL1 (ho-
mozygous OR ¼ 1.59, p ¼ 1.36 3 106), reinforcing the
fact that both additive and recessive tests are capable of de-
tecting the same common variants, regardless of the true
underlying mode of inheritance (Figure S4). The results
from both tests did not show any inflation from the null
distribution, suggesting that the case and control subjects
were well matched for ancestry and that there was no
major excessive homozygosity found in the cases. We
further applied FET on the allele counts for rare variants
(<1% allele frequency) but did not observe any inflation,
further suggesting that there is no major stratification be-
tween case and control subjects, even in the rare variants
(Figure S5). Next, we applied RAFT to the data set and
observed departure from the null distribution only among
the common variants (R5% allele frequencies) and rare
variants (<1% allele frequencies), but not the low-fre-
quency variants (1%–5% allele frequencies).
The top hit from applying the RAFTapproach (excluding
common variants—the strongest of which, as noted, flag
known associations with T2D) was a rare missense variant
(rs202042386; c.1189A>G [p.Ile397Val]) with 0.4% allele
frequency in the overall sample in BBS10 (p ¼ 1.38 3
106) with three homozygotes found in case subjects and
none in control subjects (Table 1). Given that we tested
34,673 variants with <1% allele frequency, the study-
wide significance threshold is approximately 0.05/
34,673 ¼ 1.43 106, and the c.1189A>Gmissense variant
in BBS10 is thus study-wide significant.
Of note, this allele appears to be enriched in Finns, ap-
pearing at 0.4% in this sample, and is vanishingly rare
outside of Finland—appearing at only one copy in more
than 13,000 chromosomes in the Europeans and African
Americans from the Exome Variant Server despite514 The American Journal of Human Genetics 95, 509–520, November 6, 2014
Figure 3. The p.Ile397Val Residue Is Not Conserved across 46 Vertebrates, and the Valine Residue Is Found in Other Vertebratesexcellent average coverage (~923) in the data.We explored
the region of homozygosity around the BBS10 c.1189A>G
variant in the three cases and found that they shared a 7
Mbp homozygous region in common. In addition, we
found that the three homozygotes have longer runs of ho-
mozygosity than most other individuals in the data set
(Figure S6), but they are not outliers in terms of inbreeding
coefficients (Figure S7), suggesting that the homozygosity
for the BBS10 c.1189A>G variant in these three individuals
arose from a single founder haplotype.
In Silico Prediction for BBS10 c.1189A>G
BBS10 is a small 2-exon gene located on the q-arm of chro-
mosome 12. It encodes a protein that is 723 amino acids
long (~81 kDa). Recessive mutations in BBS10 have beenThe Americanreported to result in BBS,15 a multisystemic ciliopathy
often characterized by vision or hearing loss, polydactyly
(additional fingers), autism, and obesity. The BBS10
c.1189A>G variant was predicted by in silico tools such
as PolyPhen-2,20 SIFT,21 GERP,22 and phastCons23 to be
benign or tolerated. Multiple sequence alignment across
46 vertebrates showed that the variant is not conserved
and that there are several vertebrates with the samemutant
valine amino acid as the T2D homozygotes, such as the
rhesus, baboon, rat, pika, dog, hedgehog, elephant, and
rock hyrax (Figure 3). However, we note that these verte-
brates, with the exception of the rock hyrax, had a cysteine
amino acid prior to the valine amino acid. In human,
chimp, orangutan, and kangaroo rat, the isoleucine at
position 397 was preceded by a serine amino acid. It isJournal of Human Genetics 95, 509–520, November 6, 2014 515
possible that the valine amino acid found in the three ho-
mozygotes with T2D results in disease in humans when it
is preceded by the serine amino acid.
Detailed Phenotyping for the Three Homozygotes
Given theknownrelevanceof recessive-actingmutations in
BBS10 todiabetes-relatedphenotypes, theborderline study-
wide significant finding at BBS10 c.1189A>Gwas sufficient
to evaluate this variant further. Since manifestations of
BBS include not only T2D but also obesity24 (MIM
601665), we surveyed the phenotypic data available for
these three individuals. Upon re-examination of their
medical records, we found that one of the individuals had
bilateral hypoacusis or partial hearing loss, a characteristic
often associated with BBS. Two of the homozygotes are
obese (body mass index [BMI] ¼ 39.2, age ¼ 70; BMI ¼
37.73, age ¼ 67), and one of them is overweight (BMI ¼
28.83, age ¼ 69). The lipid levels for one of the individuals
(BMI ¼ 37.7) showed that most of her lipid measurements
are in the normal range (total cholesterol¼ 22nd percentile,
low-density lipoprotein ¼ 19th percentile, high-density
lipoprotein ¼ 14th percentile), but she has elevated levels
of triglycerides in the 91st percentile, consistent with the
obesity status. None of the three individuals were reported
to have cardinal phenotypes associated with BBS such as
polydactyly, intellectual disability, cystic kidney disease,
or retinal dystrophy.
Functional Evaluation of BBS10 c.1189A>G
We have shown previously that suppression of most
BBS-associated genes during zebrafish embryogenesis leads
to convergent extension defects indicative of defective
noncanonicalWnt signaling, likely through compromised
proteasomal activity.15–17,25,26 This tool has been used
previously to annotate systematically nonsynonymous
changes by using in vivo complementation, where candi-
date alleles are introduced into human mRNA and are
then tested by their ability to rescue morphant pheno-
types.17 Microinjection of translation blocker morpholino
to knockdown bbs10 in zebrafish embryos gave rise to
convergent extension defects (Figure 4A), reproducing
previously reported phenotypes.15 Although coinjection
of human wild-type BBS10 mRNA reduced significantly
the proportion of zebrafish embryos with convergent
extension defects, essentially to the level of control em-
bryos, coinjection of human BBS10 mRNA encoding the
c.1189A>G variant failed to rescue the phenotype, sug-
gesting that c.1189A>G variant is a loss-of-function allele
(Figure 4B). Therefore, in vivo functional testing supports
the pathogenicity of the c.1189A>G variant as discovered
by the RAFT analysis.
Previous glucose tolerance test studies in this model
organism have shown that glucose treatment leads to
increased mRNA level of several genes, including pdk2
and runx1,27 suggesting that these genes participate in
the pathway that functions to tolerate high glucose. To
further test this hypothesis and evaluate the role of the516 The American Journal of Human Genetics 95, 509–520, Novembc.1189A>G variant, we coinjected the zebrafish embryos
with bbs10 morpholino and human BBS10 mRNA. We
observed that suppression of bbs10 in embryos treated
with glucose results in decreased expression of pdk2 and
runx1 and that these phenotypes could be rescued by coin-
jection of human BBS10 wild-type mRNA, but not mRNA
encoding the BBS10 c.1189A>G variant (Figure 4C). These
observations suggest that bbs10 might be involved in the
glucose tolerance pathway in the zebrafish embryos, and
that the c.1189A>G variant in human BBS10 is a loss-of-
function allele with regards to this assay, further support-
ing the pathogenicity of the c.1189A>G allele.Screening for Homozygotes in Other BBS-Associated
Genes in T2D Case and Control Subjects
Given our observation that a rare variant in BBS10 contrib-
utes to T2D risk in a recessive manner, we screened for
additional rare homozygotes (found at <1% allele fre-
quency in Europeans from the Exome Variant Server) in
the other 17 genes that have been associated with BBS28
in a larger superset of 4,947 T2D case subjects and 9,201
control subjects with exome chip genotyping data avail-
able (Table S4). Including the BBS10 c.1189A>G variant,
we observed a total of 11 homozygotes in the case subjects,
compared to 6 in the control subjects (OR¼ 3.41, 95% con-
fidence interval ¼ [2.41, 4.41], Fisher’s exact test p ¼
0.019). Excluding the three homozygotes for the BBS10
c.1189A>G variant, there is a still modest excess of homo-
zygotes observed in the case subjects (OR¼ 2.48, 95% con-
fidence interval ¼ [1.42, 3.54], Fisher’s exact test p ¼
0.095). It might be possible to identify which variants in
these additional BBS-associated genes might also be associ-
ated with T2D in future studies involving larger sample
sizes.Discussion
In this study, we describe an approach to detect rare com-
plex-disease-associated recessive alleles that might be
missed by conventional methods. The application of this
approach on a T2D exome chip data set consisting of
~4,500 Finnish individuals revealed one such significant
finding, c.1189A>G in BBS10 (p ¼ 1.38 3 106), while a
conventional analysis using Fisher’s exact test yielded
insignificant p values for both allelic (p ¼ 0.25) and homo-
zygous (p ¼ 0.07) counts. While there are confounding
issues in applying RAFT to a case-control data set, such as
population stratification and substructure, we have ad-
dressed these both conventionally (by matching case and
control subjects for ancestry by using principal-compo-
nent analysis, as well as by confirming the null distribution
of standard association tests) and with elements unique to
the RAFT analysis. Specifically, miscalled hemizygosity
arising from common deletions in the genome uncovering
a rare variant (as well as general genotyping errors) that
result in site-specific excesses of homozygotes are handleder 6, 2014
Figure 4. In Vivo Knockdown and Rescue
Experiments in Zebrafish for BBS10
c.1189A>G
(A) Lateral view (top) and dorsal view (bot-
tom) of representative zebrafish embryos at
the 10-somite stage. In comparison with
control embryos, embryos injected with
bbs10 translation blocker (TB) morpholino
exhibited an expanded body gap angle
(marked with blue lines in lateral view)
and elongated somites (marked with blue
lines in dorsal view) and kinked notochord
(marked with blue arrows in dorsal view),
indicating convergent extension (CE) de-
fects. Scale bar represents 100 mM.
(B) Distribution of zebrafish embryos with
different CE defect severity levels based
on previously established criteria (class I,
mild; class II, severe15–17 in each condi-
tion). Coinjection of human wild-type hu-
man BBS10 mRNA (bbs10 TB þ BBS10
wild-type) rescues CE defect in bbs10 TB-in-
jected embryos, while coinjection of hu-
man BBS10 mRNA with c.1189A>G muta-
tion (bbs10 TB þ BBS10 c.1189A>G) does
not. Chi-square test was used to test signif-
icance; ***p < 0.001.
(C) The relative mRNA levels of the genes
pdk2 and runx1 in 4 days postfertilization
(dpf) zebrafish embryos treated with 1%
D-glucose at 1 dpf. Decreased mRNA levels
in bbs10 TB-injected embryos were signifi-
cantly rescued by coinjection of human
wild-type human BBS10 mRNA (bbs10 TB
þ BBS10 wild-type), but not coinjection of
human BBS10 mRNA encoding the
c.1189A>G mutation (bbs10 TB þ BBS10
c.1189A>G). t test was used to test signifi-
cance; *p < 0.05, **p < 0.01, ***p < 0.001.by the simultaneous identical analysis in control subjects
and genome-wide inflation due to substructure managed
by a specific correction to the expected homozygosity as
a function of frequency.
Previously, we have shown that in an ascertained case-
control cohort, there is more power to detect rare risk
variants compared to rare protective variants.29 Similarly
in this study, the case subjects were selected for genotyp-
ing because of their T2D status, whereas the control sub-
jects were drawn from a larger population of individuals
without T2D. As such, we have applied the RAFT
method in a one-tailed test to screen for only rare reces-
sive variants that confer risk of T2D, that is, if there are
more rare homozygotes in T2D cases than expected. We
note that under a different study design, it might be
worthwhile testing and screening for rare protective vari-
ants as well.The American Journal of Human GenConsistent with a role of the
c.1189A>G allele in the phenotype
tested, functional studies indicated
this allele to encode a loss-of-function
change. BBS-associated genes such as
BBS4 (MIM 600374) have been impli-cated in GWASs on BMI,30 and while it is plausible that
BBS-associated genes might influence T2D through
obesity-induced mechanisms, it has also been described
that 6% of BBS subjects have T2D,31 and impaired glucose
tolerance has been observed in young BBS subjects,32 sug-
gesting that a fraction of BBS subjects might potentially
have T2D as a result of severe insulin resistance33 and
that there might be other obesity-independent mecha-
nisms involved as well.
Given that many genes such as the BBS-associated genes
can result in complex diseases such as obesity-induced
T2D, it will be interesting to systematically test and
evaluate the extent to which rare recessive variants in
BBS-associated genes influence obesity and T2D. While
our functional studies in zebrafish embryos are compel-
ling, further studies to design and optimize glucose
tolerance assays to systematically evaluate whether theseetics 95, 509–520, November 6, 2014 517
BBS-associated genes can affect glucose tolerance in adult
zebrafish will be required. It will be interesting to under-
stand whether this pathway is dependent on obesity-
associated factors, such as adipocyte dysfunction, and the
disease mechanisms behind the BBS mutations.
The discovery of rare recessive variants in critical genes
associated with complex diseases has broader implications
in terms of genetic discoveries for complex diseases as well.
For instance, rare recessive mutations in TREM2 (MIM
605086) were initially described to cause a rare disease
named the Nasu-Hakola disease34,35 (MIM 221770), char-
acterized by early-onset and severe dementia. More
recently, the region encompassing TREM2 was implicated
in GWASs on Alzheimer disease36 (MIM 104300), and
rare heterozygous variants in TREM2 were also found to
confer risk of Alzheimer disease.37,38 Similarly, further
studies will be needed for understanding whether rare het-
erozygous variants in BBS10 might result in increased risk
of T2D and obesity.
There are several potential extensions to the approach
we have described in this work. For instance, RAFT can
be modified to evaluate the significance of genes rather
than variants by estimating the frequency of rare variants
(such as loss-of-function variants or rare deleterious nonsy-
nonymous variants) across a gene, similar to estimating
the allele frequencies for variants. For instance, the ‘‘com-
posite allele frequency’’ of loss-of-function variants within
a gene can be estimated with the number of individuals
who have one loss-of-function variant on the same copy
of the gene. And similar to the single-variant version of
RAFT described in this manuscript, we can evaluate
whether the number of individuals who are recessive (har-
bor homozygous or compound-heterozygous loss-of-func-
tion variants within the same gene) are enriched beyond
the squared of the composite allele frequency. However,
one potential drawback with adopting a gene-based test
is that the high rate of benign variants can dilute any
potential signal in the gene.
In addition, the approach can also be extended and
modified for evaluating epistatic interactions across genes
and loci. To date, there are 17 genes reported to be involved
in BBS,28 and mutations in different genes can interact in
an oligogenic mode of disease transmission.39 It will be
interesting, by using methods such as RAFT and in vivo
complementation assay in zebrafish, to test whether
certain combinations of rare variants in different BBS-
associated genes can similarly confer risk of T2D or obesity
in an oligogenic manner.
Understanding the role of BBS-associated variants in
T2D and obesity can aid in genetic testing of family mem-
bers for early intervention. In addition, rare recessive vari-
ants such as BBS10 c.1189A>G can contribute to various
complex diseases, although the extent of the contribution
from such recessive variants in complex diseases is not
clear. Given the reported roles of rare recessive variation
in Mendelian diseases, it seems plausible there may be
many such variants yet to be identified in complex dis-518 The American Journal of Human Genetics 95, 509–520, Novembeases. As such, targeted methods such as RAFT may
contribute more broadly to whole-exome or whole-
genome sequencing efforts in identifying rare recessive
variants associated with complex diseases.Supplemental Data
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